Form 4: Enliven Therapeutics Director Sells Shares
Insider Transaction (Form 4)
Mika K Derynck, a Director of Enliven Therapeutics, Inc., sold 158,795 shares of common stock on August 4, 2026 for $60.21 per share.
Summary
- Option exercise/conversion: acquired 87,373 Common Stock at $2.48 ($216,685) on August 4, 2026; holds 87,373 after (Direct).
- Option exercise/conversion: acquired 27,567 Common Stock at $25.28 ($696,894) on August 4, 2026; holds 114,940 after (Direct).
- Option exercise/conversion: acquired 23,364 Common Stock at $14.85 ($346,955) on August 4, 2026; holds 138,304 after (Direct).
- Option exercise/conversion: acquired 20,491 Common Stock at $22.47 ($460,433) on August 4, 2026; holds 158,795 after (Direct).
- Open-market sale: disposed of 158,795 Common Stock at $60.21 ($9,561,587) on August 4, 2026 (Direct).
- Option exercise/conversion: disposed of 87,373 Stock Option (right to buy) on August 4, 2026 (Direct).
- Option exercise/conversion: disposed of 27,567 Stock Option (right to buy) on August 4, 2026 (Direct).
- Option exercise/conversion: disposed of 23,364 Stock Option (right to buy) on August 4, 2026 (Direct).
- Option exercise/conversion: disposed of 20,491 Stock Option (right to buy) on August 4, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $9,561,587 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Mika K Derynck — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-04 | Option exercise/conversion | Common Stock | 87,373 | $2 | $216.7K | 87,373 |
| 2026-08-04 | Option exercise/conversion | Common Stock | 27,567 | $25 | $696.9K | 114,940 |
| 2026-08-04 | Option exercise/conversion | Common Stock | 23,364 | $15 | $347.0K | 138,304 |
| 2026-08-04 | Option exercise/conversion | Common Stock | 20,491 | $22 | $460.4K | 158,795 |
| 2026-08-04 | Open-market sale | Common Stock | 158,795 | $60 | $9.6M | 0 |
| 2026-08-04 | Option exercise/conversion | Stock Option (right to buy) | 87,373 | — | — | 0 |
| 2026-08-04 | Option exercise/conversion | Stock Option (right to buy) | 27,567 | — | — | 0 |
| 2026-08-04 | Option exercise/conversion | Stock Option (right to buy) | 23,364 | — | — | 0 |
| 2026-08-04 | Option exercise/conversion | Stock Option (right to buy) | 20,491 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-04 | Option exercise/conversion (87,373 shares) |
| 2026-08-04 | Option exercise/conversion (27,567 shares) |
| 2026-08-04 | Option exercise/conversion (23,364 shares) |
| 2026-08-04 | Option exercise/conversion (20,491 shares) |
| 2026-08-04 | Open-market sale (158,795 shares) |
| 2026-08-04 | Option exercise/conversion (87,373 shares) |
| 2026-08-04 | Option exercise/conversion (27,567 shares) |
| 2026-08-04 | Option exercise/conversion (23,364 shares) |
| 2026-08-04 | Option exercise/conversion (20,491 shares) |
Keywords
insider transaction, Form 4, ELVN, Enliven Therapeutics, Inc., bearish, Mika K Derynck
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.